NEW ORAL ANTICOAGULANTS IN THE THERAPY OF ANTIPHOSPHOLIPID SYNDROME
The vitamin K antagonist warfarin is an essential medicine from a group of anticoagulants, which is used to treat antiphospholipid syndrome (APS). However, it has a number of disadvantages especially in patients who need longterm and frequently lifetime prevention of thromboses. New oral anticoagula...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2016-07-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2221 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849240150375137280 |
|---|---|
| author | M. A. Satybaldyeva T. M. Reshetnyak |
| author_facet | M. A. Satybaldyeva T. M. Reshetnyak |
| author_sort | M. A. Satybaldyeva |
| collection | DOAJ |
| description | The vitamin K antagonist warfarin is an essential medicine from a group of anticoagulants, which is used to treat antiphospholipid syndrome (APS). However, it has a number of disadvantages especially in patients who need longterm and frequently lifetime prevention of thromboses. New oral anticoagulants, such as dabigatran etexilate (Pradaxa®), rivaroxaban (Xarelto®), apixaban (Eliquis) and others, have been recently synthesized. Unlike warfarin, they are administered at fixed doses, require neither routine monitoring nor diet, and interact with drugs only in small amounts. The new oral anticoagulants have been approved for certain indications, but the data of performed trials are inapplicable to patients with APS. These medicines are expected to improve quality of life in patients with this condition. |
| format | Article |
| id | doaj-art-62bb5273712b4667a2fdb6b47cac5a6b |
| institution | Kabale University |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2016-07-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-62bb5273712b4667a2fdb6b47cac5a6b2025-08-20T04:00:41ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922016-07-0154221922610.14412/1995-4484-2016-219-2262096NEW ORAL ANTICOAGULANTS IN THE THERAPY OF ANTIPHOSPHOLIPID SYNDROMEM. A. Satybaldyeva0T. M. Reshetnyak1V.A. Nasonova Research Institute of Rheumatology, MoscowV.A. Nasonova Research Institute of Rheumatology, MoscowThe vitamin K antagonist warfarin is an essential medicine from a group of anticoagulants, which is used to treat antiphospholipid syndrome (APS). However, it has a number of disadvantages especially in patients who need longterm and frequently lifetime prevention of thromboses. New oral anticoagulants, such as dabigatran etexilate (Pradaxa®), rivaroxaban (Xarelto®), apixaban (Eliquis) and others, have been recently synthesized. Unlike warfarin, they are administered at fixed doses, require neither routine monitoring nor diet, and interact with drugs only in small amounts. The new oral anticoagulants have been approved for certain indications, but the data of performed trials are inapplicable to patients with APS. These medicines are expected to improve quality of life in patients with this condition.https://rsp.mediar-press.net/rsp/article/view/2221antiphospholipid syndromeprevention of thrombosesoral anticoagulants |
| spellingShingle | M. A. Satybaldyeva T. M. Reshetnyak NEW ORAL ANTICOAGULANTS IN THE THERAPY OF ANTIPHOSPHOLIPID SYNDROME Научно-практическая ревматология antiphospholipid syndrome prevention of thromboses oral anticoagulants |
| title | NEW ORAL ANTICOAGULANTS IN THE THERAPY OF ANTIPHOSPHOLIPID SYNDROME |
| title_full | NEW ORAL ANTICOAGULANTS IN THE THERAPY OF ANTIPHOSPHOLIPID SYNDROME |
| title_fullStr | NEW ORAL ANTICOAGULANTS IN THE THERAPY OF ANTIPHOSPHOLIPID SYNDROME |
| title_full_unstemmed | NEW ORAL ANTICOAGULANTS IN THE THERAPY OF ANTIPHOSPHOLIPID SYNDROME |
| title_short | NEW ORAL ANTICOAGULANTS IN THE THERAPY OF ANTIPHOSPHOLIPID SYNDROME |
| title_sort | new oral anticoagulants in the therapy of antiphospholipid syndrome |
| topic | antiphospholipid syndrome prevention of thromboses oral anticoagulants |
| url | https://rsp.mediar-press.net/rsp/article/view/2221 |
| work_keys_str_mv | AT masatybaldyeva neworalanticoagulantsinthetherapyofantiphospholipidsyndrome AT tmreshetnyak neworalanticoagulantsinthetherapyofantiphospholipidsyndrome |